secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-11-12T21:41:11+00:00
Accession:  0001193125-26-458624
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Rallybio expects Avenzo merger to close Nov 20; sets $13.90/share cash distribution
--------------------------------------------------------------------------------

- Avenzo Therapeutics merger under May 31, 2026 agreement expected to close after market close Nov 20, 2026; Nasdaq approved listing of common stock for the deal.
- Special cash distribution of $13.90/share to holders of record Nov 5, 2026; deposit with transfer agent Nov 19, payments expected to begin Nov 30, 2026.
- Nasdaq due-bill period runs from Nov 5 record date through close on Nov 20; buyers in that period receive the cash distribution, while sellers do not.
- Reverse stock split expected effective 4:01 p.m. ET on Nov 20, 2026; timing and amount of the cash distribution are unaffected.
- Contingent value rights expected distributed Nov 23, 2026 to common holders, pre-funded warrants, RSUs and In the Money Parent Options as of Nov 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526458624/0001193125-26-458624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526458624/d176721d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-458624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer